

“  
Preimplantation genetic  
screening for aneuploidy is  
characteristic for all  
up-to-date PGD methods  
”

but also without aneuploidies; thus, we significantly increase the embryo implantation rate and decrease the abortion rate.

It comes as no surprise, that preimplantation genetic screening for aneuploidy is characteristic for all up-to-date PGD methods. Why focus only on a specific single-gene disorder and overlook all risks linked to aneuploidies, if we have the means to target both, the single gene disorders and aneuploidies, at the same time?

**Claim 1:** An increasing number of couples cannot be effectively treated for infertility, without the use of up-to-date genetic methods.

**Claim 2:** Karyomapping is suitable for any rare inherited disorder with a known causal mutation.

**Claim 3:** Only the PGS method is suitable for a full analysis of all chromosomes.

*MUDr. Kateřina Veselá, Ph.D. was born on 21. 5. 1966. She successfully graduated from the Faculty of Medicine, Masaryk University Brno and has obtained a postgraduate certification in obstetrics and gynecology. She acquired her Ph.D. title in the field of medical biology and genetics. Currently she acts as a managing director in RE-PROMEDA, a center of assisted reproduction medicine and genetics. In 2000, the first successful cycles with preimplantation genetic diagnostics in Central Europe were carried out under her supervision. Her center of assisted reproduction currently performs approximately 500 preimplantation genetic diagnostic runs annually. She is now an internationally respected specialist in the field of reproductive medicine and genetics.*

